NCT02842099Unknown2 期
A Randomized, Phase II Study Comparing Standard Chemotherapy (TA-Taxol+Epirubicin or TAC-Taxol+Epirubicin+Cyclophosphamide) With Standard Chemotherapy (TA or TAC) Followed by Capecitabine (X) as Prolonged Postoperative Adjuvant Treatment for Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- Disease-free survival
研究概览
简要总结
The study is a prospective, randomized phase II clinical trial, to compare the efficacy and safety profiles of standard chemotherapy versus standard chemotherapy followed by capecitabine as prolonged postoperative adjuvant treatment for breast cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age >= 18 and <= 70 years old.
- •Performance status (Karnofsky index) >=
- •Histological diagnosis of invasive breast cancer (T1-T4,N2-3,M0). Time window between surgery and study randomization must be less than 60 days.
- •Surgery must consist of mastectomy or conserving surgery with axillary lymph node dissection.
- •Positive axillary lymph nodes defined as at least 1 out of 10 nodes with presence of disease. If sentinel node technique is used, sentinel node can be the only node affected.
- •Status of hormone receptors, HER2 status, Ki-67 index and p53 in primary tumour. Results must be available before the adjuvant chemotherapy. All patients require the TA or TAC chemotherapy. And patients should receive the endocrine chemotherapy or anti-targeted therapy according to the hormone receptor status or HER2 status respectively.
- •Written informed consent. Patients are able to comply with treatment and study follow-up.
- •Patients must not present evidence of metastatic disease.
- •Normal electrocardiogram (EKG) in the 12 weeks prior to randomization. If needed, normal cardiac function must be confirmed by left ventricular ejection fraction (LVEF).
- •Laboratory results (within 14 days prior to randomization):
- •Hematology: neutrophils >= 2.0x10^9/l; platelets >= 100x10^9/l; hemoglobin >= 10 mg/dl;
- •Hepatic function: total bilirubin <= 1 upper normal limit (UNL); SGOT and SGPT <= 2.5 UNL; alkaline phosphatase <= 2.5 UNL. If values of SGOT and SGPT > 1.5 UNL are associated to alkaline phosphatase > 2.5 UNL, patient is not eligible;
- •Renal function: creatinine <= 175 mmol/l (2 mg/dl); creatinine clearance >= 60 ml/min.
- •Complete stage workup during the 12 weeks prior to randomization (mammograms are allowed within a 20 week window). All patients must have a bilateral mammogram, thorax x-ray, abdominal echography and/or computed tomography (CT)-scan. If bone pain, and/or alkaline phosphatase elevation, a bone scintigraphy is mandatory. This test is recommended for all patients. Other tests: as clinically indicated.
- •Negative pregnancy test done in the 14 prior days to randomization.
排除标准
- •Prior systemic therapy for breast cancer.Or prior therapy with anthracyclines or taxanes (paclitaxel or docetaxel) for any malignancy.
- •Prior radiotherapy for breast cancer.
- •Bilateral invasive breast cancer.
- •Pregnant or lactating women. Adequate contraceptive methods must be used during chemotherapy and hormone therapy treatments.
- •Any N0-1 or M1 tumour.
- •Pre-existing grade >= 2 motor or sensorial neurotoxicity (National Cancer Institute Common Toxicity Criteria version 2.0 [NCI CTC v-2.0]).
- •Any other serious medical pathology, such as congestive heart failure; unstable angina; history of myocardial infarction during the previous year; uncontrolled HA or high risk arrhythmias.
- •History of neurological or psychiatric disorders, which could preclude the patients from free informed consent.
- •Active uncontrolled infection.
- •Active peptic ulcer; unstable diabetes mellitus.
- •Previous or current history of neoplasms different from breast cancer, except for skin carcinoma, cervical in situ carcinoma, or any other tumour curatively treated and without recurrence in the last 10 years; ductal in situ carcinoma in the same breast; lobular in situ carcinoma.
- •Chronic treatment with corticosteroids.
- •Contraindications for corticosteroid administration.
- •Concomitant treatment with raloxifene, tamoxifen or other selective estrogen receptor modulators (SERMs), either for osteoporosis treatment or for prevention. These treatments must stop before randomisation.
- •Concomitant treatment with other investigational products; participation in other clinical trials with a non-marketed drug in the 20 previous days before randomization.
- •Concomitant treatment with another therapy for cancer.
研究组 & 干预措施
TA or TAC plus X
Experimental
Standard chemotherapy (TA or TAC) followed by capecitabine 2.5g, po, qd for one year.
干预措施: TA or TAC (Drug)
TA or TAC plus X
Experimental
Standard chemotherapy (TA or TAC) followed by capecitabine 2.5g, po, qd for one year.
干预措施: X (Drug)
TA or TAC
Active Comparator
Standard chemotherapy (TA or TAC) followed by no more chemotherapy
干预措施: TA or TAC (Drug)
结局指标
主要结局
Disease-free survival
时间窗: 5 years
Adverse event rate (CTCAE v. 3.0)
时间窗: 5 years
次要结局
- Overall survival(5 years)
研究者
Qiang SUN
Chief of Dept. Breast Surgery, Professor
Peking Union Medical College Hospital
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
X Versus Placebo as Postoperative Adjuvant Treatment for Elder Breast CancerBreast CancerNCT02838238Peking Union Medical College Hospital300
Unknown
2 期
Adjuvant Afatinib in Stage I-III NSCLC With EGFR MutationNon Small Cell Lung CancerNCT01746251Massachusetts General Hospital92
进行中（未招募）
2 期
Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical CancerCervical CancerNCT03340376Universitaire Ziekenhuizen KU Leuven48
进行中（未招募）
2 期
Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain ManagementTotal Knee ArthroplastyNCT05561309Shanghai Hengrui Pharmaceutical Co., Ltd.89
招募中
2 期
Phase Ⅱ Study of Intercostal Nerve Block With HR18034 for Postsurgical Pain ManagementThoracoscopic LobectomyNCT05744674Shanghai Hengrui Pharmaceutical Co., Ltd.96